Hepatitis C
CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals
- Details
- Category: Experimental HCV Drugs
- Published on Saturday, 18 February 2017 00:00
AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
CROI 2017: New HCV Infections Among HIV+ Gay Men Drop By Half After DAA Roll-Out in Netherlands
- Details
- Category: HCV Sexual Transmission
- Published on Friday, 17 February 2017 00:00
A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the hepatitis C treatment, researchers have already seen a dramatic decline in acute HCV infections among one at-risk population, HIV-positive men who have sex with men, according to findings reported at the Conference on Retroviruses and Opportunistic Infections this week in Seattle.
AASLD 2016: Curing Hepatitis C Reduces Liver-Related Complications and Death
- Details
- Category: HCV Disease Progression
- Published on Wednesday, 18 January 2017 00:00
People with hepatitis C who achieve sustained virological response to treatment had lower liver-related morbidity and mortality rates compared to patients who were not successfully treated, according to research presented at the recent AASLD Liver Meeting.
CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?
- Details
- Category: HCV Disease Progression
- Published on Friday, 17 February 2017 00:00
HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
AASLD 2016: Liver Cirrhosis and Decompensation on the Rise Among People with Hepatitis C
- Details
- Category: HCV Disease Progression
- Published on Tuesday, 17 January 2017 00:00
Complications of advanced liver disease including cirrhosis and hepatic decompensation have risen over the past decade among people with chronic hepatitis C, according to study findings presented at the AASLD Liver Meeting in November. However, in recent years the increase has slowed, especially among those at highest risk -- black patients and people age 60 and over.
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: Hepatitis B
- Published on Thursday, 02 February 2017 00:00
HIVandHepatitis.com coverage of the 2016 Liver Meeting, annual conference of the American Association for the Study of Liver Diseases, AASLD), November 11-15, 2016, in Boston.
Gilead and AbbVie Seek FDA Approval of Pangenotypic Hepatitis C Treatments
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 27 December 2016 00:00
Gilead Sciences and AbbVie both announced this month that they have applied for U.S. Food and Drug Administration approval of new all-oral ribavirin-free combination regimens to treat all genotypes of hepatitis C virus (HCV). Gilead's sofosbuvir/velpatasvir/ voxilaprevir and AbbVie's glecaprevir/pibrentasvir have demonstrated high cure rates in Phase 3 clinical trials.
AASLD 2016: Is DAA Treatment for Hepatitis C Reducing the Need for Liver Transplants?
- Details
- Category: HCV Disease Progression
- Published on Sunday, 22 January 2017 00:00
Patients successfully treated for hepatitis are less likely to need liver transplants and less likely to die while on a transplant waiting list, according to studies presented at the recent AASLD Liver Meeting. A related analysis looked at the optimal timing of treatment for people awaiting transplants in order to avoid "MELD purgatory."
8. More Treatment Options for More Types of HCV
- Details
- Category: HCV Treatment
- Published on Thursday, 22 December 2016 00:00
This year saw the approval of new highly effective direct-acting antiviral therapies for hepatitis C, with more in the pipeline and due for approval in 2017.
More Articles...
- 9. Primary Care Providers Can Treat Hepatitis C
- AASLD 2016: Real-World Studies Show 8 Weeks of Sofosbuvir/Ledipasvir Equals 12 Weeks for Many Patients
- AASLD 2016: Generic Sofosbuvir Underperforms in Real World, May Be Due to Suboptimal Regimens
- AASLD 2016: Glecaprevir/ Pibrentasvir Effective for Hepatitis C Patients with Severe Kidney Disease
- AASLD 2016: Curing Hepatitis C May Help Reduce Kidney Disease Progression
Web Design and Development by